Literature DB >> 11053009

Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans.

M Feldman1, K Shewmake, B Cryer.   

Abstract

Aspirin causes peptic ulcers predominately by reducing gastric mucosal cyclooxygenase (COX) activity and prostaglandin synthesis. Because aspirin circulates for only a few hours, we hypothesized that aspirin's inhibitory effect on gastric COX activity must be prolonged. We performed a placebo-controlled experiment in healthy humans to determine the duration of inhibition of aspirin on gastric mucosal COX activity (PGE(2) and PGF(2alpha) synthesis rates). Recovery of gastric COX activity after stopping aspirin was slow and linear. Seventy-two hours after 325-mg aspirin, gastric COX activity was still reduced by 57% (P < 0.001). Duration of inhibition of gastric COX activity was estimated to be 7-8 days after 325-mg aspirin and 5 days after 81-mg aspirin. Recovery of gastric prostaglandin synthesis after 325-mg but not after 81-mg aspirin occurred at slower rates in subjects with Helicobacter pylori-associated gastritis than in those with normal histology. In conclusion, aspirin inhibits gastric COX activity for much longer than predicted from its pharmacokinetic profile, explaining why aspirin at widely spaced intervals is ulcerogenic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053009     DOI: 10.1152/ajpgi.2000.279.5.G1113

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  9 in total

1.  Endoscopy in asymptomatic minidose aspirin consumers.

Authors:  Yaron Niv; Alex Battler; Galia Abuksis; Eyal Gal; Boris Sapoznikov; Alex Vilkin
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

2.  Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle.

Authors:  Stephen M Ratchford; Kaleen M Lavin; Ryan K Perkins; Bozena Jemiolo; Scott W Trappe; Todd A Trappe
Journal:  J Appl Physiol (1985)       Date:  2017-07-13

3.  Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers.

Authors:  Dymphy R H Huntjens; David J M Spalding; Meindert Danhof; Oscar E Della Pasqua
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

4.  Minidose aspirin and gastrointestinal bleeding--a retrospective, case-control study in hospitalized patients.

Authors:  Boris Sapoznikov; Alex Vilkin; Marcella Hershkovici; Michal Fishman; Rami Eliakim; Yaron Niv
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

Review 5.  Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.

Authors:  Sebastian Harder; Ute Klinkhardt; John M Alvarez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction.

Authors:  Ravi Vachhani; Doumit Bouhaidar; Alvin Zfass; Bimaljit Sandhu; Ali Nawras
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

7.  Influence of low-dose aspirin, resistance exercise, and sex on human skeletal muscle PGE2 /COX pathway activity.

Authors:  Masatoshi Naruse; William A Fountain; Alex Claiborne; Toby L Chambers; Andrew M Jones; Andrew M Stroh; Cristhian F Montenegro; Colleen E Lynch; Kiril Minchev; Scott Trappe; Todd A Trappe
Journal:  Physiol Rep       Date:  2021-03

8.  Stability of acetylsalicylic acid in human blood collected using volumetric absorptive microsampling (VAMS) under various drying conditions.

Authors:  Seol Ju Moon; Song-Hee Han; Yong-Geun Kwak; Min-Gul Kim
Journal:  Transl Clin Pharmacol       Date:  2022-03-17

9.  Enhanced prostacyclin synthesis by adenoviral gene transfer reduced glial activation and ameliorated dopaminergic dysfunction in hemiparkinsonian rats.

Authors:  May-Jywan Tsai; Ching-Feng Weng; Nien-Chu Yu; Dann-Ying Liou; Fu-San Kuo; Ming-Chao Huang; Wen-Cheng Huang; Kabik Tam; Song-Kun Shyue; Henrich Cheng
Journal:  Oxid Med Cell Longev       Date:  2013-04-03       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.